PO.MCB10.02 · 分子与细胞生物学

利用嵌合eCLIP揭示头颈癌中血统相关的非编码RNA

Using chimeric eCLIP to uncover ancestry-related noncoding RNAs in head and neck cancer

海报缩略图:利用嵌合eCLIP揭示头颈癌中血统相关的非编码RNA
编号 5901 展板 8 时间 4/21 02:00–05:00 区域 Section 20 主讲 Chayil Lattimore, BS
分会场 Functional Roles of Noncoding RNAs in Cancer Progression, Metabolism, and Therapy Response
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Chayil C. Lattimore, Lu Li, Lauren Gay, Rolf Renne, Mingyi Xie, Kristianna M. Fredenburg

University of Florida, Gainesville, FL

摘要 Abstract

中文摘要
引言:嵌合增强型交联免疫沉淀(eCLIP)是一种高通量方法,可直接绘制Argonaute(Ago)介导的RNA相互作用图谱。据我们所知,该方法从未用于研究癌症结局中的血统差异。我们在非洲和欧洲血统的头颈癌细胞系中进行了嵌合eCLIP,目的是鉴定可能凸显与血统相关的肿瘤行为和治疗反应差异的经典和非经典RNA相互作用。 方法:我们从癌症基因组图谱(TCGA)头颈癌队列中不同血统背景的患者中提取基因表达数据。使用差异表达分析(edgeR)鉴定差异表达基因(FDR < 0.05,-1 < log((FC)) > 1),并进行KEGG通路分析以鉴定通路富集(p adj. < 0.05)。使用miRnet生成miRNA-靶点预测。使用混合分析验证头颈癌细胞系的血统。在这些细胞系上进行嵌合eCLIP方案。简言之,将Ago蛋白与其天然RNA相互作用伙伴共价交联。进行Ago免疫沉淀。将RNA片段磷酸化并连接以生成RNA-RNA嵌合体。文库经反转录、PCR扩增和大小选择,以限制接头二聚体污染。通过Illumina NovaSeq进行双端测序(150 bp读长)。 结果:自我报告为非洲血统患者中高表达的基因富集于药物代谢通路(p= 8.31E-10),而低表达基因富集于肌动蛋白细胞骨架功能(p= 3.22E-52)。miRnet预测与药物代谢和肌动蛋白细胞骨架功能相关的基因受miR-200、miR-99和miR-143/145家族成员调控,这些成员在细胞生长和存活、上皮-间质转化及细胞骨架完整性中发挥作用。初步eCLIP数据支持该预测,突显了如miR-100-5p/ABCF2、miR-200c-3p/CDK6和miR-141-3p/ITGB8等miRNA-mRNA配对。 结论:我们呈现了与头颈癌相关的血统相关非编码RNA调控的证据。未来分析将涉及差异结合分析、通路富集分析以及与SNP的遗传叠加,以确定与血统的关联。总体而言,该方法可用于揭示其他结局不同的癌症中的通路。本摘要使用ChatGPT进行语言编辑和文本润色。
查看英文原文 English abstract
Introduction: Chimeric enhanced cross-linking and immunoprecipitation (eCLIP) is a high-throughput method that enables direct mapping of Argonaute (Ago)-mediated RNA interactions. To our knowledge, this method has never been used to investigate ancestral differences in cancer outcomes. We performed chimeric eCLIP in African and European-ancestry head and neck cancer cell lines, with the goal of identifying canonical and non-canonical RNA interactions that may underscore differences in tumor behavior and therapeutic response related to ancestry. Methods: We abstracted gene expression data from patients in the Cancer Genome Atlas (TCGA) head and neck cancer cohort with different ancestral backgrounds. Differential expression analysis (edgeR) was used to identify differentially expressed genes (FDR < 0.05, -1 < log((FC)) > 1) and KEGG pathway analysis was performed to identify pathway enrichment (p adj. < 0.05). miRNA-target predictions were generated using miRnet. Admixture analysis was used to validate ancestry from head and neck cancer cell lines. Chimeric eCLIP protocol was performed on these cell lines. Briefly, Ago proteins were covalently cross-linked to their native RNA interaction partners. Ago immunoprecipitation was performed. RNA fragments were phosphorylated and ligated to generate RNA-RNA chimeras. Libraries were reverse transcribed, PCR amplified, and size selected to limit adapter dimer contamination. Paired-end sequencing (150 bp reads) was performed via Illumina NovaSeq. Results: Higher expressed genes in patients with self-reported African ancestry were enriched for drug metabolic pathways (p= 8.31E -10 ), while lower expressed were enriched for actin cytoskeletal function (p= 3.22E -52 ). miRnet predicted genes associated with drug metabolism and actin cytoskeletal function to be regulated by miR-200, miR-99, and miR-143/145 family members, which play a role in cell growth and survival, epithelial-mesenchymal transition, and cytoskeletal integrity. Preliminary eCLIP data supports this prediction, highlighting miRNA-mRNA pairings such as miR-100-5p/ABCF2, miR-200c-3p/CDK6, and miR-141-3p/ITGB8. Conclusion: We present evidence of ancestry-related noncoding RNA regulation associated with head and neck cancer. Future analyses will involve differential binding analysis, pathway enrichment analysis, and genetic overlay with SNPs to determine associations with ancestry. Overall, this methodology may be used to uncover pathways in other cancers with differing outcomes. ChatGPT was used for language editing and text refinement of this abstract.
利益披露 Disclosure
C. C. Lattimore, None.. L. Li, None.. L. Gay, None.. R. Renne, None.. M. Xie, None.. K. M. Fredenburg, None.

← 返回 AACR 2026 检索